Mazdutide , a dual GLP-1/glucagon agonist, is in development and shows promising results in early trials, particularly in Asian populations
However, it is important to keep perspective: the most effective medication is the one that works for your body, fits your health profile, and can be maintained consistently over time
Tirzepatide , on the other hand, favors sustained receptor retention at the plasma membrane with reduced cytosolic trafficking
These events are well recognised with incretin-based therapies such as GLP-1 receptor agonists, and retatrutide has shown a similar pattern in the early studies
Rapid weight reduction may involve mobilization of glycogen stores and associated water weight
Open Retatrutide Calculator How to Use This Chart Understand the status: Retatrutide is investigational and not FDA-approved